Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 654727, 9 pages
http://dx.doi.org/10.1155/2014/654727
Research Article

IDH1/IDH2 but Not TP53 Mutations Predict Prognosis in Bulgarian Glioblastoma Patients

1Molecular Medicine Center, Medical University of Sofia, 2 Zdrave Street, 1431 Sofia, Bulgaria
2Department of Medical Chemistry and Biochemistry, Medical Faculty, Medical University of Sofia, 2 Zdrave Street, 1431 Sofia, Bulgaria
3Department of Neurosurgery, University Multiprofile Hospital for Active Treatment and Emergency Medicine “N.I.Pirogov”, 21 Totleben Boulevard, 1606 Sofia, Bulgaria
4Department of Pathology, University Multiprofile Hospital for Active Treatment and Emergency Medicine “N.I.Pirogov”, 21 Totleben Boulevard, 1606 Sofia, Bulgaria

Received 20 February 2014; Accepted 29 March 2014; Published 24 April 2014

Academic Editor: Eiichi Ishikawa

Copyright © 2014 Gergana Stancheva et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Mutations in genes encoding isocitrate dehydrogenase isoforms 1 (IDH1) and 2 (IDH2) have been associated with good prognosis for patients with brain neoplasias and have been commonly found together with mutated TP53 gene. To determine the prevalence of IDH1, IDH2, and TP53 mutations and their impact on overall survival 106 glioblastoma patients were analysed. IDH1 mutations were detected in 13 and IDH2 mutation in one patient. Two homozygous samples with R132H mutation in IDH1 gene and a novel aberration K129R in IDH2 gene were found. Sixty-four percent of IDH1/IDH2 mutated tumours harboured also a mutation in TP53 gene. Genetic aberrations in TP53 were present in 37 patients. Statistical analysis of the impact of the studied factors on the overall survival showed that the mutations in IDH1/IDH2, but not the ones in TP53, were associated with longer survival. Also, the impact of age on prognosis was confirmed. This is the first comprehensive study on glioblastomas in Bulgaria. Our results suggest that IDH1/IDH2 but not TP53 mutations together with other prognostic factors such as age might be applied in clinical practice for prediction of outcome in patients with glioblastomas.